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Chlorpromazine, which was discovered in 1952, has an
exhaustively characterized efficacy/safety profile compris-
ing serious limitations: effectiveness in the field failing to
match efficacy in trials, residual symptoms in 50% of
patients, a 20% relapse rate in compliant patients, and
worrisome extrapyramidal side effects, including tardive
dyskinesia in 5% per year. Second-generation “atypical”
antipsychotics bypass these effects by having less affinity
for the dopamine D2 receptor and affinities for other neu-
roreceptors. Clozapine, the lead atypical antipsychotic, was
followed in the mid 1990s by risperidone, olanzapine, and
quetiapine, which now account for over half of new
antipsychotic prescriptions in North America. The debate
over their relative efficacy involves the potential well-being
of millions of schizophrenics and billions of dollars. Atypi-
cal antipsychotics are considerably more expensive; evi-
dence for their superiority is highly variable and often
inadequate, largely confined to short-term regulatory stud-
ies. Their effects on long-term outcome (particularly neg-
ative symptoms), relapse prevention, social and vocational
functioning, suicide prevention and quality of life, and
family and caregiver burden are largely unknown. The
National Institute of Mental Health’s Clinical Antipsychotic
Trials of Intervention Effectiveness (CATIE) project is a com-
bined efficacy–effectiveness trial that aims to answer these
questions in a broad range of patients with schizophre-
nia and Alzheimer’s disease.
he modern era of treating psychotic disorders
began in 1952 with the discovery that the compound
chlorpromazine possessed antipsychotic properties and
produced symptomatic improvement in patients with
schizophrenia. Initially, chlorpromazine was termed a
neuroleptic drug (derived from the Greek neuron and
lepsis,meaning to “take hold of the nervous system”) to
describe its effects of psychomotor immobilization.The
implication was that the therapeutic antipsychotic prop-
erties and adverse motor effects were inextricably
linked.Thus,chlorpromazine and the numerous antipsy-
chotic compounds that followed were initially consid-
ered to belong to a class of neuroleptic drugs in which
therapeutic effects were inseparable from the
extrapyramidal side effects (EPSs) they produced.
1
Conventional antipsychotic drugs
Conventional antipsychotic drugs or neuroleptics are
known to be efficacious in treating psychotic symptoms.
However, almost half a century of experience with con-
ventional antipsychotic drugs has revealed their sub-
stantial limitations.To varying degrees, all conventional
antipsychotics carry the risk of side effects, including
EPSs,hyperprolactinemia,and the neuroleptic malignant
syndrome.
2 The most worrisome form of EPS, tardive
dyskinesia (TD),can be irreversible and its incidence has
been estimated at about 5% a year.
3 These medication
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Clinical researchside effects contribute to treatment nonadherence,
which, in turn, leads to relapse and rehospitalization.
Efforts to minimize EPSs have revealed that lowering
the dose decreases side effects, but risks decreased effi-
cacy and relapse.
4 In addition, the traditional antipsy-
chotics do not alleviate all of the symptoms and disabil-
ity caused by schizophrenia;at least 50% of patients have
persisting or residual symptoms and disability despite
treatment,
5 and at least 20% of patients relapse despite
taking adequate doses of medication.
6,7A substantial pro-
portion of patients continue to be severely disabled and
relapse frequently,due to either treatment nonadherence
or ineffective treatment.
8-10 The hospitalizations and
rehospitalizations that result from relapse produce sub-
stantial human suffering and significant financial costs to
mental health systems.
11-16
Thus,despite substantial data from controlled trials that
support the efficacy of conventional antipsychotic med-
ications for the positive symptoms of schizophrenia,the
effectiveness of these agents in everyday practice is sub-
stantially less than their efficacy as determined in care-
fully controlled clinical trials. Although many factors
may be involved, we do not know all the causes of this
efficacy–effectiveness gap.
17 We do know, however, that
the scientific and clinical promises of antipsychotic ther-
apy have not been fully realized,and patients with schiz-
ophrenia remain vulnerable to a downward spiral of
hospitalization, noncompliance, relapse, rehospitaliza-
tion,and persistent disability.
Atypical antipsychotic drugs
The advent of the second generation of antipsychotic
drugs has changed the risk/benefit profile of these med-
ications.Clozapine was the prototype of the second gen-
eration of antipsychotics,and it has shifted the emphasis
of drug development toward the search for drugs that
have the same beneficial effects, without the risk of
agranulocytosis caused by clozapine and without the
EPSs that accompany treatment with the first-genera-
tion antipsychotics.Some of the newer medications,like
olanzapine and quetiapine, are structurally similar to
clozapine, while others, such as risperidone and ziprasi-
done, have a different structure, but share some of its
key pharmacological features.
It is widely accepted that the actions of typical antipsy-
chotics involve their ability to block the dopamine D2
receptors in the limbic system and striatum.It is thought
that the blockade of receptors in the limbic system is the
basis for the antipsychotic action; the reduction in the
activity of the striatum contributes to the EPSs (and pos-
sibly the development of TD);and the D2 blockade of the
hypothalamic–pituitary axis leads to hyperprolactinemia.
The new drugs differ pharmacologically from conven-
tional antipsychotics principally in their lower affinity
for the D2 receptor and relatively greater affinities for
other neuroreceptors, including those for serotonin 
(5-HT1A,5-HT2A,5-HT2C,5-HT3,5-HT6,and 5-HT7) and
norepinephrine (α 1 and α 2 subtypes),and in their ability
to modulate glutamate receptor–mediated functions and
behaviors.
18 A pharmacological property that has been
emphasized as critical for conferring atypical activity is
the ratio between D2 and 5-HT2A receptor antagonism;a
low ratio is characteristic of the new agents.
19 In addi-
tion, they appear to exhibit some degree of regional
anatomic specificity, altering neurochemical activity in
the limbic and frontal cortical regions,while having very
little effect on the corpus striatum.
20
A variety of characteristics in addition to neuroreceptor
affinities,including effects in animal models,potentially
greater efficacy in treating negative,cognitive,and mood
symptoms, and lower propensity to cause EPSs, have
been used to identify and define the new antipsy-
chotics.
18,21 In this article,“atypical antipsychotic” refers
to clozapine, olanzapine, quetiapine, risperidone, and
ziprasidone.Amisulpride has also been proposed as an
atypical antipsychotic.However,because of its more tra-
ditional mechanism of action,we have not included it in
this discussion.However,this does not negate the possi-
bility that it may warrant inclusion as a second genera-
tion of atypical antipsychotic.Sertindole is not included
because it is no longer available for clinical use.Because
clozapine is the prototype and has unique risks and ben-
efits, the others will be referred to as “newer” atypical
antipsychotics.Conventional antipsychotic drugs—typi-
fied by low-potency chlorpromazine, intermediate-
potency perphenazine, and high-potency haloperidol—
are those introduced before 1990.
Comparison of conventional and atypical
antipsychotic drugs
Various claims have been made with regard to the supe-
riority in efficacy and safety of the atypical antipsy-
chotics relative to the conventional drugs.This has pre-
cipitated an important debate that is now underway
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regarding the appropriate role of the second-generation
or atypical antipsychotic drugs in treating schizophre-
nia.At issue are the potential well-being of millions of
persons with schizophrenia and billions of dollars.
The debate concerns the relative efficacy of atypical and
conventional antipsychotic drugs,their side effects,their
effectiveness for patients in everyday settings,and their
cost-effectiveness.The atypical antipsychotics cost con-
siderably more than the conventional drugs they may
replace.If the additional costs of atypical antipsychotics
are not justified by their benefits,this information could
significantly influence clinicians and policy makers in
resource allocation decisions.For example,in the USA,
where the dissemination of medical technology is largely
determined by market forces,atypical antipsychotics are
widely used,while countries with more systematic health
care planning and budgeting have been more deliberate
in adopting these new products.
Although a variety of claims of efficacy and safety of
atypical antipsychotics compared with conventional
agents have been made, the evidence is highly variable
and in many cases inadequate. Some questions can be
answered from the available literature and data from
studies presented at scientific meetings, but many more
cannot. There is now strong evidence that atypical
antipsychotics are efficacious in schizophrenia, and that
they are associated with a lower risk of EPSs than con-
ventional antipsychotic drugs.
22 However, a comprehen-
sive understanding of the nature and extent of any clini-
cal advantages of the atypical antipsychotics over their
conventional counterparts is not available. The advan-
tages of the atypical antipsychotics regarding EPSs and
TD may be offset by disadvantages in terms of other side
effects.For example,it appears that the atypical antipsy-
chotics as a class produce substantial weight gain to a
greater degree than conventional antipsychotics. Clini-
cal trials of the efficacy and safety of the atypical antipsy-
chotics show weight gain in as many as 50% to 80% of
study subjects.
23 Although these reports indicate that
weight gain is an effect shared by the atypical antipsy-
chotics, the individual drugs may vary in the magnitude
of this effect.Clozapine and olanzapine have been asso-
ciated with the most dramatic weight gain,while ziprasi-
done may produce the least weight gain of the atypical
antipsychotics examined for this effect thus far.
24 The
physiological mechanism of weight gain is unknown.Also
unknown are consequences of the weight effects.These
could range in severity from mild cosmetic changes to
significant disfigurement to increased rates of cardiovas-
cular disease,diabetes,and mortality.
Atypical antipsychotic drugs have also been associated
with alterations in glucose metabolism and with eleva-
tions of blood cholesterol and lipids.
24-26 Two recently
published case series described 10 patients on atypical
antipsychotics who either developed diabetes or had a
significant exacerbation of existing disease.
25,26 Looking
at both reports combined,weight gain occurred in 60%
of subjects prior to the development of diabetes. The
relationships between the atypical antipsychotic effects
on weight gain and the effects on glucose, cholesterol,
and lipids are not known.Also not known are the long-
term medical consequences of all these effects.It is quite
possible that the nutritional and metabolic effects of the
atypical antipsychotics could pose safety problems that
are as onerous to patients treated with them as TD was
to patients treated with conventional antipsychotics.
Two meta-analyses of studies of atypical antipsychotics
have recently received widespread attention.The first,by
Leucht and colleagues, examined the safety and efficacy
of olanzapine,quetiapine,and risperidone,from random-
ized controlled trials.
22 (Sertindole was also examined,but
is not mentioned further here because it is no longer
available due to alleged cardiac toxicity.) This meta-analy-
sis evaluated the change in overall psychopathology to
measure global efficacy,the change in negative symptoms,
the use of antiparkinsonian medications as a measure of
side effects, dropouts due to treatment failure, and
dropouts due to adverse events.All the atypical antipsy-
chotics and haloperidol were superior to placebo regard-
ing global efficacy,with olanzapine and risperidone “very
modestly” superior to haloperidol. Regarding negative
symptoms,all the atypical antipsychotics and haloperidol
were superior to placebo.The analyses showed olanzapine
and risperidone as superior to haloperidol,and quetiapine
as inferior to haloperidol in treating negative symptoms.
However, when sub- and supratherapeutic doses were
examined,quetiapine was just as effective as haloperidol
in treating negative symptoms. All the newer atypical
antipsychotics were better than haloperidol regarding the
use of antiparkinsonian medications and were similar to
each other. Risperidone was closer to haloperidol than
the other newer atypical antipsychotics regarding the use
of antiparkinsonian drugs.
Geddes and colleagues examined 52 randomized con-
trolled trials that compared atypical antipsychotics
(including amisulpride and sertindole) with conventional
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antipsychotics or with other atypical antipsychotics.
21
Examined outcomes included symptom scores, dropout
rates,and scores on measures of side effects.Overall,they
found that atypical antipsychotics were slightly more
effective and better tolerated than conventional antipsy-
chotics.Thus,the conclusions of both major meta-analyses
were consistent with regard to effectiveness and tolera-
bility. However, Geddes and colleagues also noted that
the advantage of atypical antipsychotics increased as the
dose of the conventional comparator increased.They con-
ducted additional analyses using only doses of conven-
tional antipsychotics that did not exceed recommenda-
tions (haloperidol 12 mg daily or equivalent) and no
longer found differences in dropout rates between the
atypical and conventional antipsychotics. On the other
hand,even when excessive doses of conventional antipsy-
chotics were excluded from analyses,fewer EPSs occurred
with atypical antipsychotics.Nevertheless,on the basis of
the finding that many of the perceived benefits were due
to excessive doses of the conventional comparator drugs,
Geddes and colleagues found that the atypical antipsy-
chotics have no clear advantage in terms of either efficacy
or tolerability.They concluded that the atypical antipsy-
chotics’ apparent advantage in terms of EPSs was not
enough to improve their overall tolerability or to war-
rant recommending them as first-line treatments.
To summarize the existing evidence, it is reasonably
clear that atypical antipsychotics are at least as effec-
tive as the conventional antipsychotics in reducing pos-
itive symptoms in patients with schizophrenia. Claims
that they are superior in reducing positive symptoms
have not yet been proven.
21,22 Olanzapine and risperi-
done appear to be slightly more effective than conven-
tional antipsychotics in reducing negative symptoms,but
it is not clear whether this is due to a direct therapeutic
effect or to less frequent EPSs or other secondary causes
of negative symptoms.
21 Long-term trials of the effec-
tiveness of atypical antipsychotics in reducing negative
symptoms are needed.
7 Existing studies have found that
atypical antipsychotics cause fewer EPSs than their con-
ventional counterparts,especially when the conventional
comparator is haloperidol.In spite of marketing claims,
studies of effects on cognitive function are wholly incon-
clusive,as are studies of the effects on mood symptoms.
The effects of these drugs on long-term outcome,relapse
prevention, social and vocational functioning, suicide
prevention,quality of life,and family and caregiver bur-
den have just begun to be explored.
Although first introduced only in the mid-1990s,risperi-
done,olanzapine,and quetiapine now account for more
than half the new antipsychotic prescriptions in the USA
and Canada. The rates of usage vary in Europe, Asia,
and South America from as low as 5% to as much as
40%. Patients who had inadequate therapeutic
responses to conventional antipsychotics or who suf-
fered problematic side effects were the first to be
switched to the atypical antipsychotics. Now, however,
many newly diagnosed or first-episode patients are ini-
tially prescribed these newer agents with the hope (not
yet backed by evidence) of giving them every early
advantage.
27Worldwide,many patients with schizophre-
nia continue treatment with the conventional antipsy-
chotics.Because there are no long-acting atypical prepa-
rations yet available, conventional antipsychotics in a
long-acting injectable form retain an important role for
patients who cannot adhere to oral regimens. (At the
beginning of 2001, a long-acting version of risperidone
was in phase 2 trials.)
Atypical antipsychotic medications are several times
more expensive than conventional antipsychotics in the
USA, averaging $5000 or more per patient per year.
Thus, these medications have substantial potential for
influencing the use of scarce resources.While their high
cost may discourage their use,they have the potential to
generate substantial savings in health and non–health
care resources if they are more cost-effective than other
available treatments.Even if atypical antipsychotic drugs
do not decrease the overall costs of care,their use may be
warranted if their benefits are judged to be substantial
enough to justify the increased expenditure.The clinical
and public policy decision to supplant conventional with
atypical antipsychotic treatment requires empirical evi-
dence. This is important because the spending of large
sums of money on treatments that are less cost-effective
than available alternatives may result in needless waste
of scarce resources and deprive some patients of clinical
benefits to which they would otherwise have access.
The evidence to support the superior effectiveness of
atypical antipsychotics over conventional antipsychotics
is currently limited and predominantly based on short-
term efficacy studies. Existing evidence does not ade-
quately address long-term effectiveness and cost issues.
The studies to date, which were for the most part spon-
sored by pharmaceutical companies and designed to
achieve regulatory approval based on evidence of effi-
cacy and safety, are largely short term (6–8 weeks),
Clinical research377
Effectiveness of antipsychotic drugs in schizophrenia - Stroup et al Dialogues in Clinical Neuroscience - Vol 2 . No.4 . 2000
involve initially hospitalized patients, and focus mainly
on the core psychopathology of schizophrenia and well-
known side effects (eg, EPSs). These studies do not
definitively demonstrate the “real world” effects of the
newer atypical antipsychotics, nor do they adequately
examine the broad range of side effects that may occur.
At the same time, however, these studies provide evi-
dence of greater safety for these medications,at least in
terms of rates of EPSs and TD, and the possibility of
superior therapeutic benefits in psychopathologic and
functional domains that have not, as yet, been ade-
quately or fully evaluated.
Conclusion
Existing evidence suggests some, albeit inconsistent,
advantages in efficacy and tolerability for the newer
atypical antipsychotics over the conventional antipsy-
chotics for patients with schizophrenia. However, the
limited types of assessment measures used and the short
study durations do not provide adequate information
about treatment for this highly variable and chronic con-
dition. Moreover, the patient samples involved in these
studies and the conditions imposed by the restrictions of
the protocols limit the generalizability of the results.
Additional information, from studies not sponsored by
pharmaceutical companies, is needed to inform clini-
cians and policy makers about appropriate role of atyp-
ical antipsychotics.
Several studies are currently ongoing or in preparation
to examine the comparative effectiveness of atypical
antipsychotics.The one with which we are most familiar
is the Clinical Antipsychotic Trials of Intervention Effec-
tiveness (CATIE) project,a major research initiative in
the USA by the National Institute of Mental Health,
which will assess the effectiveness of the second-gener-
ation antipsychotics in a broad range of patients with
schizophrenia and in patients with Alzheimer’s disease.
The CATIE trial in schizophrenia combines elements
of efficacy and effectiveness trials. Medications will be
randomly assigned on a double-blind basis. Follow-up
will be up to 2 years. The primary outcome will be all-
cause treatment discontinuation, and this will be vali-
dated by measures of symptoms, side effects, quality of
life,and costs.The study will examine strategies for what
to do when a patient fails an initial trial of an atypical
antipsychotic drug.For example,should a second newer
atypical antipsychotic be prescribed or is clozapine the
best choice? In addition,the trial seeks to avoid some of
the problems that have been criticized in earlier trials.
Instead of high-potency haloperidol, medium-potency
perphenazine is the conventional comparator.The dose
of the conventional comparator will not be excessive.
Cost–effectiveness and cost–benefit analyses will be con-
ducted to help identify the value of any advantages that
atypical antipsychotics may have over conventional
antipsychotics or over each other. Ultimately, the
CATIE trial in schizophrenia seeks to provide crucial
information regarding the role of atypical antipsychotic
medications for patients with schizophrenia.In addition
to the CATIE Project, the Medical Networks in Medi-
cine (MEDNET) is examining the comparative effec-
tiveness of different drug groups in their indicated dis-
orders in Germany (W. Gaebel, H. J. Moller, personal
communication). At the same time, in many countries,
investigators have no government support for research
on mental disorders and their treatment.An alternative
approach is to utilize funding from a consortium of phar-
maceutical companies to support investigator-initiated
clinical trials, such as was done by the European First-
Episode Treatment Study in Schizophrenia (EUFEST)
group (W. Fleischhacker, R. Kahn, personal communi-
cation).
These studies will contribute to the body of evidence
that is needed to definitively evaluate the effectiveness
of the atypical antipsychotic drugs and determine their
proper use. ❏
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Eficacia comparada de antipsicóticos en 
la esquizofrenia
La clorpromazina, que fue descubierta en 1952,
tiene un perfil de eficacia / seguridad amplia-
mente caracterizado que incluye serias limitacio-
nes: la eficacia en la práctica clínica es menor a la
de los ensayos clínicos, hay síntomas residuales
en el 50% de los pacientes, hay un 20% de reca-
ídas en pacientes que están adheridos al trata-
miento y se presentan desagradables efectos
secundarios extrapiramidales, incluyendo la dis-
quinesia tardía en un 5% por año. Los antipsicó-
ticos “atípicos” evitan estos efectos al tener
menos afinidad por el receptor D2 de dopamina
y sí afinidades por otros neurorreceptores. La clo-
zapina, líder entre los antipsicóticos atípicos, fue
seguida a mediados de la década de los 90 por
risperidona, olanzapina y quetiapina, los que
ahora dan cuenta de más de la mitad de las pres-
cripciones de nuevos antipsicóticos en América
del Norte. El debate acerca de su eficacia relati-
va involucra el potencial bienestar de millones de
esquizofrénicos y billones de dólares. Los antip-
sicóticos atípicos de segunda generación son con-
siderablemente más caros, las evidencias acerca
de su superioridad son altamente variables y a
menudo inadecuadas y se limitan a estudios de
regulación de corta duración. Los efectos de la
evolución a largo plazo (particularmente los sín-
tomas negativos), la prevención de recaídas, el
funcionamiento social y vocacional, la preven-
ción de suicidios y la calidad de vida, y el costo
para las familias y cuidadores son poco conoci-
dos. El proyecto acerca de la eficacia de inter-
vención de los ensayos clínicos de antipsicóticos
del National Institute of Mental Health es un
estudio de eficacia – eficiencia cuyo objetivo es
responder a estas preguntas en una amplia
población de pacientes con esquizofrenia y
enfermedad de Alzheimer.
Efficacité comparative des traitements
antipsychotiques dans la schizophrénie
La chlorpromazine, découverte en 1952, et dont
les caractéristiques d'efficacité/sécurité d'emploi
ont été dressées de façon exhaustive, comporte
de sérieuses limitations. En effet, l’efficacité réel-
le de la chlorpromazine n'atteint pas celle déter-
minée dans les études, 50 % des patients souf-
frent de symptômes résiduels, 20 % des patients
rechutent malgré une bonne observance. Par
ailleurs, la chlorpromazine entraîne l'apparition
d'effets secondaires extrapyramidaux préoccu-
pants, telle la dyskinésie tardive dont l'incidence
est de 5 % par an. Les antipsychotiques de secon-
de génération, dits “atypiques”, évitent ces pro-
blèmes du fait qu'ils ont une affinité moindre
pour les récepteurs dopaminergiques D2, tout en
possédant une affinité pour d'autres neuroré-
cepteurs. La clozapine, chef de file des antipsy-
chotiques atypiques, a été suivie dans le milieu
des années 90 par la rispéridone, l’olanzapine et
la quetiapine qui représentent à l’heure actuelle
plus de la moitié des prescriptions d’antipsycho-
tiques en Amérique du Nord. Le débat quant à
leur efficacité relative intéresse le bien-être
potentiel de millions de schizophrènes et un
marché portant sur des milliards de dollars. Les
nouveaux antipsychotiques coûtent en effet
beaucoup plus cher et leur supériorité, très
variable et souvent insuffisante, n'est confirmée
que dans des essais à court terme à visée régle-
mentaire. L'effet à long terme de ces médica-
ments sur le devenir de la maladie (en particulier
sur les symptômes négatifs), la prévention des
rechutes et des suicides, l’insertion sociale et pro-
fessionnelle, la qualité de vie et la charge sup-
portée par l’entourage familial et le personnel
soignant sont autant d’inconnues. C'est pour élu-
cider ces points que le projet CATIE (Clinical Anti-
psychotic Trials of Intervention Effectiveness),
une étude d'efficacité/efficience, est actuelle-
ment mené sous l'égide du National Institute of
Mental Health chez un grand nombre de
patients atteints de schizophrénie et de la mala-
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